{"id":"NCT03941093","sponsor":"FibroGen","briefTitle":"Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer","officialTitle":"A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-10","primaryCompletion":"2024-06-11","completion":"2024-06-11","firstPosted":"2019-05-07","resultsPosted":"2024-11-05","lastUpdate":"2024-11-05"},"enrollment":284,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pancreatic Cancer Non-resectable"],"interventions":[{"type":"DRUG","name":"Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX","otherNames":["FG-3019","Gemzar","Abraxane","Eloxitan","Leucovorin","Camptosar","5-Fluracil","Efudex"]},{"type":"DRUG","name":"Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX","otherNames":["Gemzar","Abraxane","Eloxitan","Leucovorin","Camptosar","5-Fluracil","Efudex"]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Up to approximately 5 years","effectByArm":[{"arm":"Pamrevlumab + Gemcitabine/Nab-paclitaxel or FOLFIRINOX","deltaMin":17.25,"sd":null},{"arm":"Placebo + Gemcitabine/Nab-paclitaxel or FOLFIRINOX","deltaMin":17.94,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5487"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["United States","Austria","Belgium","Canada","China","France","Germany","Israel","Italy","South Korea","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.fibrogen.com/"]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":142},"commonTop":["Diarrhoea","Fatigue","Nausea","Anaemia","Alopecia"]}}